LLY or ABBV: Which Drugmaker is Likely to Offer Better Upside in 2026?

Lilly's Mounjaro and Zepbound drove $36.5B of sales in 2025 (≈56% of company revenue) while AbbVie's Skyrizi and Rinvoq generated $26.0B in 2025 and are expected to exceed $31B in 2026. Zacks consensus implies 2026 sales/EPS growth of +25.7%/+41.1% for LLY and +9.6%/+45.6% for ABBV; LLY trades at ~25.1x forward EPS vs ABBV ~13.8x, and dividend yields ~0.8% (LLY) vs 2.3% (ABBV). Key risks: Lilly faces U.S. price declines and rising GLP‑1 competition (including Novo Nordisk's oral Wegovy), while AbbVie contends with Humira biosimilar erosion and weakness in aesthetics; Lilly is preferred for growth, AbbVie for valuation/income.

Analysis

Lilly and AbbVie are operating from distinct optionality prisms: Lilly’s optionality is product-adoption and modality substitution (injectable → oral → next-gen agonists), while AbbVie’s is execution on durable immunology franchises and redeploying excess cash into tuck-ins. The most consequential second-order effect is on the supply chain and commercialization layer — a successful oral GLP-1 materially reduces cold-chain and pen‑device demand, compressing revenue pools for injectables CMOs and specialty pharmacy logistics over 12–36 months, while increasing addressable primary‑care scripts and retail pharmacy volumes.

Regulatory and payer dynamics will be the decisive catalysts over the next 6–18 months. The FDA decisions and label language for oral small molecules and triple-agonists set adoption ceilings; simultaneous insurer formulary moves (step edits, prior-authorizations, rebate restructurings) can swing realized price realization by mid‑teens percentage points within a single commercial cycle. AbbVie’s near-term tail risks are execution and aesthetics cyclical weakness; its re-rating is contingent on continuing above‑trend uptake for two core immunology brands and disciplined M&A integration across the next 2–4 quarters.

Trade implementation should prioritize convexity and capital efficiency: capture upside from product approvals and continued uptake while protecting against rapid pricing compression from payers. Use option structures to define maximum capital at risk around key binary events (label approvals, Q2–Q3 2026 launches, quarterly prints) and size pair trades to neutralize sector beta. Positioning should be nimble around FDA calendars and insurer statement windows rather than calendar quarters alone.

The consensus risk is behavioral: the market price assumes either perpetual high growth for GLP‑1 pricing power or a smooth transition for AbbVie from legacy to growth franchises. Both are binary mispricings — GLP‑1s face concentrated payer leverage and potential margin resets, while AbbVie’s valuation currently understates the value of a low‑LOE immunology run rate plus optionality from disciplined buyouts. That creates asymmetric, event-driven opportunities for defined‑risk structures.

Key Decisions for Investors

• Long ABBV equity (12‑18 month horizon) size 2–4% portfolio with a protective 9–12 month 7–12% OTM put: objective capture ~15–30% upside from continued immunology execution while limiting downside from aesthetics weakness or a single-quarter miss.
• Long LLY via a 9–12 month call‑spread (buy near‑ATM calls, sell 20–30% OTM calls) to target approval/uptake convexity around oral GLP‑1 and late‑stage triple‑agonist readouts; costed spread limits capital and yields 2–4x upside if adoption continues versus a capped loss if payers blunt pricing.
• Pair trade: long ABBV / short LLY (equity-weighted to neutralize biotech beta) over 6–12 months to play valuation mean reversion — reduces market direction risk and isolates dispersion between durable immunology cashflow and growth‑at‑a‑premium GLP‑1 exposure.
• Event hedge: buy a short‑dated (3–6 month) index put on Healthcare ETFs or a small cap biotech basket ahead of major insurer formulary decisions and FDA advisory meetings to protect against correlated downside if payers enact broad step edits.